Which weight loss injection is safest — and how do you decide?

"Safe" is the right question, but it needs a more precise frame

A common misconception is that one injection is universally safer than the other and that choosing it protects you regardless of context. That isn't quite how it works. Both Mounjaro and Wegovy have passed the MHRA's rigorous licensing process, and both are backed by phase-3 trial data involving thousands of participants. The safety question that actually matters is: safe for whom, sourced from where, and under what level of clinical oversight?

Mounjaro (tirzepatide) activates two gut-hormone receptors (GIP and GLP-1) making it the only dual-agonist weight-management medicine licensed in the UK. Wegovy (semaglutide) works on the GLP-1 pathway alone. Both slow gastric emptying, reduce appetite, and have been studied extensively in adults with obesity. The comparison between the two is a clinical conversation, not a safety ranking. According to NHS guidance on tirzepatide, the medicine should only be started under the supervision of a healthcare professional who has reviewed your full medical history.

The frame that serves you best: not "which is safest" but "which is appropriate for me, and am I getting it through a route I can trust." Those are two distinct questions, and both matter.

What the licensed safety profile actually covers, and what warrants urgent attention

Both injections share a broadly similar side-effect pattern. Digestive symptoms (nausea, vomiting, diarrhoea, constipation, reflux) are the most frequently reported and are most noticeable when starting or moving up in dose. They are real, can be uncomfortable, and for most people ease within days to a couple of weeks. Fatigue, headache and injection-site reactions also appear in trial data.

Less common but more serious: the MHRA's Drug Safety Update published on 29 January 2026 highlighted acute pancreatitis as an infrequent but potentially serious risk associated with GLP-1 medicines. The signal to act on is severe stomach pain that radiates to the back, with or without vomiting. That warrants same-day medical contact, not a wait-and-see approach. You can report any suspected side effect through the MHRA's Yellow Card scheme, which is also where you can flag suspect sellers.

Other reasons to seek prompt advice: gallbladder symptoms, signs of dehydration after prolonged vomiting or diarrhoea, or any allergic reaction. People with a personal or family history of medullary thyroid cancer or MEN2 syndrome, or a history of pancreatitis, need to discuss this with a prescriber before starting either medicine. Neither injection is recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They are not licensed for people under 18.

Why the source of your injection matters as much as the medicine itself

This is where the safety question becomes urgent in a different way. The MHRA has issued repeated warnings about counterfeit weight loss pens circulating online and through social media. Fake pens have been found to contain insulin rather than the labelled medicine, a potentially life-threatening substitution. In October 2025, enforcement teams raided the first known UK site manufacturing counterfeit tirzepatide pens. Roughly 20 million doses of illegally traded weight-loss medicines, with an estimated street value of around £45 million, were seized across 2025 enforcement operations.

A licensed injection bought through a pharmacy you cannot verify on the GPhC register is not the same product as one dispensed by a GPhC-registered pharmacy working within the licensed UK supply chain. You can check any online pharmacy at the GPhC's public register. Red flags include medicines offered without a clinical assessment, prices dramatically below the market range, and discount codes attached to prescription medicines from unfamiliar sellers. If you want broader context on what low prices sometimes mean for safety, that page covers it honestly.

For anyone weighing up the safest route to a weight loss injection, the supply chain is not a secondary consideration. It is part of the safety answer.

Eligibility and what a prescriber actually assesses

Both injections are licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI that meets the threshold is the starting point, not the finish line.

A prescriber will look at your full picture: other medicines you take (oral contraceptives and some other medications interact with tirzepatide in particular), existing conditions, and what you have tried before. If you are still exploring your options and want to understand what the injections used for weight loss are actually called, that page gives a clear overview of the medicines and their brand names. NICE's appraisal of tirzepatide (TA1026, published December 2024) sets out the clinical criteria in detail. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. A named clinician reads your answers; the process involves photo-ID verification, live weight confirmation on video, and a check of relevant clinical history before anything is prescribed. You can read about our clinical team's approach if that kind of transparency matters to you.

If you'd like to understand what you might be eligible for, check your eligibility with a free consultation, there's no obligation and no charge for the assessment itself. You may also find it helpful to read about which weight loss injections are considered the safest, particularly if you want to go into that consultation with a clearer sense of the options available to you.